Recent patents of DNA methylation biomarkers in gastrointestinal oncology

Recent Patents on DNA and Gene Sequences

Volumn 4, Issue 3, 2010, Pages 202-209

  Corvalan, Alejandro H ^a   Maturana, Maria J ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Biomarkers; Circulating DNA; DNA methylation; Gastrointestinal tumors; Microrna; Sources of DNA; Tumor suppressor genes

Indexed keywords

ACTIVATED PROTEIN C; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 2; CYCLOOXYGENASE 2; DEATH ASSOCIATED PROTEIN KINASE; DNA; FOLLISTATIN RELATED PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; MIR 342; PEPSINOGEN I; PEPSINOGEN II; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN TYROSINE PHOSPHATASE SHP 1; TMEFF1 PROTEIN; TRANSCRIPTION FACTOR RUNX3; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; COLORECTAL CARCINOMA; DISEASE MARKER; DNA DETERMINATION; DNA METHYLATION; EARLY DIAGNOSIS; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; FECES ANALYSIS; GENE SILENCING; GENETIC RISK; HUMAN; LYMPHADENECTOMY; NONHUMAN; PATENT; PRIORITY JOURNAL; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH JUICE; STOMACH LAVAGE; TREATMENT RESPONSE;

ADENOCARCINOMA; CYCLOOXYGENASE 2; DNA; DNA METHYLATION; EPIGENOMICS; ESOPHAGEAL NEOPLASMS; GASTRIC JUICE; GASTRIC LAVAGE; GASTROINTESTINAL NEOPLASMS; HUMANS; MICRORNAS; PATENTS AS TOPIC; RNA INTERFERENCE; SULFITES; TUMOR MARKERS, BIOLOGICAL;

EID: 79952746328     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221510794751695     Document Type: Article

References (96)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
2. Parkin DM. International variation. Oncogene 2004; 23(38): 6329-40.
3. Hyatt BJ, Paull PE, Wassef W. Gastric oncology: an update. Curr Opin Gastroenterol 2009; 25(6): 570-8.
4. Meza-Junco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer. Expert Opin Biol Ther 2009; 9(12): 1543-51.
5. Holt PR, Kozuch P, Mewar S. Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. Best Pract Res Clin Gastroenterol 2009; 23(6): 889-907.
6. Ushijima T, Nakajima T, Maekita T. DNA methylation as a marker for the past and future. J Gastroenterol 2006; 41(5): 401-7.
7. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 2008; 68(1): 1-11.
8. Callinan PA, Feinberg AP. The emerging science of epigenomics. Hum Mol Genet 2006; 15 Spec No 1: R95-101.
9. Wehrum D, Grutzmann R, Hennig M, Saeger HD, Pilarsky C. Recent patents concerning diagnostic and therapeutic applications of aberrantly methylated sequences in pancreatic cancer. Recent Pat DNA Gene Seq 2008; 2(2): 97-106.
10. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16(1): 6-21.
11. Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 2003; 95(23): 1747-57.
12. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3(6): 415-28.
13. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349(21): 2042-54.
14. Hamilton JP, Sato F, Jin Z, et al. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression. Clin Cancer Res 2006; 12(22): 6637-42.
15. Bernal C, Aguayo F, Villarroel C, et al. Reprimo as a potential biomarker for early detection in gastric cancer. Clin Cancer Res 2008; 14(19): 6264-9.
16. Bernal C, Vargas M, Ossandon F, et al. DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis. Biol Res 2008; 41(3): 303-15.
17. Wu DL, Sui FY, Jiang XM, Jiang XH. Methylation in esophageal carcinogenesis. World J Gastroenterol 2006; 12(43): 6933-40.
18. Negraes PD, Favaro FP, Camargo JL, et al. DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer 2008; 8: 238.
19. Belinsky SA, Schiller JH, Stidley CA. DNA methylation biomarkers to assess therapy and chemoprevention for non-small cell lung cancer. Nutr Rev 2008; 66 (Suppl 1): S24-6.
20. Locke I, Kote-Jarai Z, Fackler MJ, et al. Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls. Breast Cancer Res 2007; 9(1): R20.
21. Rosas SL, Koch W, da Costa Carvalho MG, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNAmethyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001; 61(3): 939-42.
22. Suh CI, Shanafelt T, May DJ, et al. Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. Mol Cell Probes 2000; 14(4): 211-7.
23. van der Vaart M, Pretorius PJ. Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 2008; 1137: 18-26.
24. Watanabe Y, Kim HS, Castoro RJ, et al. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 2009; 136(7): 2149-58.
25. Zou H, Harrington J, Rego RL, Ahlquist DA. A novel method to capture methylated human DNA from stool: implications for colorectal cancer screening. Clin Chem 2007; 53(9): 1646-51.
26. Harbeck N, Nimmrich I, Hartmann A, et al. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 2008; 26(31): 5036-42.
27. Maier S, Dahlstroem C, Haefliger C, Plum A, Piepenbrock C. Identifying DNA methylation biomarkers of cancer drug response. Am J Pharmacogenomics 2005; 5(4): 223-32.
28. Ferrini AM, Mannoni V, Pontieri E, Pourshaban M. Longer resistance of some DNA traits from BT176 maize to gastric juice from gastrointestinal affected patients. Int J Immunopathol Pharmacol 2007; 20(1): 111-8.
29. Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care 2006; 10(2): R60.
30. Zeerleder S. The struggle to detect circulating DNA. Crit Care 2006; 10(3): 142.
31. Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer 2003; 103(2): 149-52.
32. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta 2007; 1775(1): 181-232.
33. Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 2003; 49(6 Pt 1): 1028-9.
34. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93(18): 9821-6.
35. Duffy MJ, Napieralski R, Martens JW, et al. Methylated genes as new cancer biomarkers. Eur J Cancer 2009; 45(3): 335-46.
36. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a highthroughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28(8): E32.
37. Marsh S. Pyrosequencing applications. Methods Mol Biol 2007; 373: 15-24.
38. Fraga MF, Uriol E, Borja DL, et al. High-performance capillary electrophoretic method for the quantification of 5-methyl 2'-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues. Electrophoresis 2002; 23(11): 1677-81.
39. Ansorge WJ. Next-generation DNA sequencing techniques. N Biotechnol 2009; 25(4): 195-203.
40. Taylor KH, Kramer RS, Davis JW, et al. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res 2007; 67(18): 8511-8.
41. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010; 10(2): 87-101.
42. Barbiere JM, Lyratzopoulos G. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review. Gastroenterology 2009; 137(6): 1869-76.
43. Laird P, Carroll C. Epigenetic sequences for esophageal adenocarcinoma. US20080096768, 2008.
44. Meltzer SJ, Cheng Y, Jin Z. Methods for predicting esophageal adenocarcinoma. WO200905533, 2009.
45. Schulmann K, Sterian A, Berki A, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005; 24(25): 4138-48.
46. Sato F, Jin Z, Schulmann K, et al. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One 2008; 3(4): e1890.
47. Nomura S, Kaminishi M. Surgical treatment of early gastric cancer. Dig Surg 2007; 24(2): 96-100.
48. Miyamoto A, Kuriyama S, Nishino Y, et al. Lower risk of death from gastric cancer among participants of gastric cancer screening in Japan: a population-based cohort study. Prev Med 2007; 44(1): 12-9.
49. Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006; 118(9): 2315-21.
50. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9(3): 279-87.
51. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345(11): 784-9.
52. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109(1): 138-43.
53. Rollan A, Ferreccio C, Gederlini A, Serrano C, Torres J, Harris P. Non-invasive diagnosis of gastric mucosal atrophy in an asymptomatic population with high prevalence of gastric cancer. World J Gastroenterol 2006; 12(44): 7172-8.
54. Karita M, Noriyasu A, Teramukai S, Matsumoto S. Atrophic progression induced by H. pylori infection is correlated with a changing pepsinogen I value and associated with the development of gastric cancer. Dig Dis Sci 2004; 49(10): 1615-20.
55. Chen TS, Lee YC, Li FY, Chang FY. Smoking and hyperpepsinogenemia are associated with increased risk for duodenal ulcer in Helicobacter pylori-infected patients. J Clin Gastroenterol 2005; 39(8): 699-703.
56. Kekki M, Samloff IM, Varis K, Ihamaki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol Suppl 1991; 186: 109-16.
57. Oishi Y, Kiyohara Y, Kubo M, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006; 163(7): 629-37.
58. Mizuno S, Kobayashi M, Tomita S, et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer 2009; 12(3): 158-63.
59. Lee TL, Leung WK, Chan MW, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 2002; 8(6): 1761-6.
60. Abbaszadegan MR, Moaven O, Sima HR, et al. p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J Gastroenterol 2008; 14(13): 2055-60.
61. Chan MW, Chu ES, To KF, Leung WK. Quantitative detection of methylated SOCS-1, a tumor suppressor gene, by a modified protocol of quantitative real time methylation-specific PCR using SYBR green and its use in early gastric cancer detection. Biotechnol Lett 2004; 26(16): 1289-93.
62. Chen Z, Fan JQ, Li J, et al. Promoter hypermethylation correlates with the Hsulf-1 silencing in human breast and gastric cancer. Int J Cancer 2009; 124(3): 739-44.
63. Cheng YY, Yu J, Wong YP, et al. Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer 2007; 97(7): 895-901.
64. Ebert MP, Model F, Mooney S, et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology 2006; 131(5): 1418-30.
65. Koike H, Ichikawa D, Ikoma H, Otsuji E, Kitamura K, Yamagishi H. Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RTPCR) in peripheral blood of gastric cancer patients. J Surg Oncol 2004; 87(4): 182-6.
66. Ikoma H, Ichikawa D, Daito I, et al. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer. Hepatogastroenterology 2007; 54(75): 946-50.
67. Ikoma H, Ichikawa D, Koike H, et al. Correlation between serum DNA methylation and prognosis in gastric cancer patients. Anticancer Res 2006; 26(3B): 2313-6.
68. Kanyama Y, Hibi K, Nakayama H, et al. Detection of p16 promoter hypermethylation in serum of gastric cancer patients. Cancer Sci 2003; 94(5): 418-20.
69. Ichikawa D, Koike H, Ikoma H, et al. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res 2004; 24(4): 2477-81.
70. Koike H, Ichikawa D, Ikoma H, et al. Comparison of serum aberrant methylation and conventional tumor markers in gastric cancer patients. Hepatogastroenterology 2005; 52(64): 1293-6.
71. Leung WK, To KF, Chu ES, et al. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer 2005; 92(12): 2190-4.
72. Tahara T, Arisawa T, Shibata T, et al. Risk prediction of gastric cancer by analysis of aberrant DNA methylation in non-neoplastic gastric epithelium. Digestion 2007; 75(1): 54-61.
73. Tang LP, Cho CH, Hui WM, et al. An inverse correlation between Interleukin-6 and select gene promoter methylation in patients with gastric cancer. Digestion 2006; 74(2): 85-90.
74. Corvalán A. Biomarker for early detection of gastric cancer. INAPI200901907, 2009.
75. Sato N, Goggins M. Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 2006; 13(4): 280-5.
76. Takahashi T, Suzuki M, Shigematsu H, et al. Aberrant methylation of Reprimo in human malignancies. Int J Cancer 2005; 115(4): 503-10.
77. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11(5): 439-49.
78. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1): 11-20.
79. Hoon D, De Maat M. Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. US20090061441, 2009.
80. Hartgrink HH, van de Velde CJ, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004; 30(6): 643-9.
81. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340(12): 908-14.
82. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22(11): 2069-77.
83. Lieberman DA. Clinical practice. Screening for colorectal cancer. N Engl J Med 2009; 361(12): 1179-87.
84. Goyle S, Maraveyas A. Chemotherapy for colorectal cancer. Dig Surg 2005; 22(6): 401-14.
85. Kwong LN, Dove WF. APC and its modifiers in colon cancer. Adv Exp Med Biol 2009; 656: 85-106.
86. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009; 60: 167-79.
87. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009; 8: 102.
88. Lopez J, Percharde M, Coley HM, Webb A, Crook T. The context and potential of epigenetics in oncology. Br J Cancer 2009; 100(4): 571-7.
89. Grady WM, Parkin RK, Mitchell PS, et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 2008; 27(27): 3880-8.
90. Tewari M. Epigenetic silencing of miR-342 in colorectal cancer. WO2009100161, 2009.
91. Takaku M, Machida S, Nakayama S, Takahashi D, Kurumizaka H. Biochemical analysis of the human EVL domains in homologous recombination. FEBS J 2009; 276(20): 5841-8.
92. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22(15): 2990-7.
93. Bestor T, Edwards J, Ju J, Li X. Universal methylation profiling methods. WO2010011312, 2010.
94. Palmer LE, Rabinowicz PD, O'Shaughnessy AL, et al. Maize genome sequencing by methylation filtration. Science 2003; 302(5653): 2115-7.
95. Lee DU, Agarwal S, Rao A. Th2 lineage commitment and efficient IL-4 production involves extended demethylation of the IL-4 gene. Immunity 2002; 16(5): 649-60.
96. Rollins RA, Haghighi F, Edwards JR, et al. Large-scale structure of genomic methylation patterns. Genome Res 2006; 16(2): 157-63.